Who Watches the Watchmen? The Fight Over America's Audit Oversight—and Why Investors Should Be Paying Attention

In the summer of 2025, the Public Company Accounting Oversight Board came within a single procedural technicality of ceasing to exist. The House Financial Services Committee had voted 30–22 along party lines to fold the PCAOB into the Securities and Exchange Commission, and the provision made it all the way into the reconciliation package that passed the House. It was the Senate Parliamentarian—not the policy merits—that ultimately kept the organization alive, ruling that the measure violated the Byrd Rule because it would increase, rather than decrease, the federal deficit.[1]

The PCAOB survived. But its institutional future remains uncertain, and the implications for investors are significant.

For institutional allocators, activist investors, and anyone whose capital is deployed on the basis of audited financial statements, the debate over audit oversight is not an abstract regulatory turf war. It is a question of whether the infrastructure underpinning trust in public company financials will be reinforced or allowed to quietly erode—and what that means for the risk profile of every equity position in every portfolio.

A Brief History Worth Remembering

The PCAOB was not created during a period of calm deliberation. It was born out of crisis. When Enron collapsed in 2001—followed in rapid succession by WorldCom, Tyco, and others—the common thread was not merely corporate fraud. It was the failure of the audit function to detect it, and in some cases, the active complicity of auditors in concealing it. Arthur Andersen, one of the largest and most storied accounting firms in the world, was destroyed in the fallout.

Congress created the PCAOB under the Sarbanes-Oxley Act of 2002 as an independent, nonprofit entity specifically because lawmakers concluded that the SEC alone had not been an effective overseer of audit quality. The audit profession’s prior system of self-regulation through peer review had failed. The PCAOB was designed to be the remedy: an independent body with the authority to inspect audit firms, set auditing standards, and bring enforcement actions when firms fell short.

For more than two decades, that model has functioned as a foundational pillar of investor confidence in U.S. capital markets.

The Current Threat Landscape

The proposal to eliminate the PCAOB did not emerge in a vacuum. It was part of a broader deregulatory agenda that gained momentum through 2025. Proponents argued that the PCAOB was duplicative of the SEC’s existing authority, that its board members’ salaries exceeded those of comparable federal officials, and that consolidation would produce cost savings. A Congressional Budget Office analysis published in May 2025, however, told a different story: eliminating the PCAOB and transferring its functions to the SEC would reduce federal spending by approximately $3.2 billion over ten years, but it would also eliminate $3.3 billion in offsetting fee collections—producing a net increase in the federal deficit of roughly $100 million.[1]

Although the legislative effort stalled, the PCAOB’s operating environment has shifted materially. Its fiscal year 2026 budget was reduced by approximately nine percent.[3] Internal dissent among board members has surfaced publicly, with one board member noting that the organization had consistently underspent its budget by more than seven percent per year since 2018—raising questions about whether the budget cuts were a signal of fiscal discipline or a prelude to further reductions in institutional capacity.[3] Meanwhile, another board member publicly advocated for a “grace period” before reporting inspection deficiencies—a concept that, if adopted, would delay the flow of critical information to the very investors the organization was designed to protect.[4]

These shifts are occurring alongside a broader recalibration of the regulatory environment governing shareholder engagement. In February 2025, the SEC issued new Compliance and Disclosure Interpretations that significantly expanded the scope of activities the agency views as “influencing control” of a public company—introducing the subjective concept of “pressure” as a potential trigger for reclassifying passive investors as active filers under Schedule 13D.[5] Separately, the SEC’s 2026 Examination Priorities explicitly identify, for the first time, investment advisers with “activist engagement practices” as an area of examination focus, referencing compliance with beneficial ownership reporting obligations under Schedules 13D and 13G.[6] Proxy advisory firms and major institutional investors, including BlackRock and Vanguard, have also recalibrated their voting guidelines to emphasize financial materiality over broader governance considerations—a shift that may further alter the dynamics of board accountability.[9] [10]

The regulatory apparatus, in short, is being recalibrated on multiple fronts simultaneously.

Why Audit Oversight Quality Is an Investment Variable

It is tempting to view the PCAOB debate as a matter of interest only to auditors and their regulators. That view misapprehends the role that audit quality plays in the investment process.

Every valuation model, every discounted cash flow analysis, every assessment of enterprise value begins with the same foundational assumption: that the financial data feeding those models is materially accurate. That assumption is underwritten by the audit opinion. And the quality of the audit opinion is, in turn, a function of the rigor with which audit firms are inspected, held accountable, and incentivized to perform at a high standard.

When audit oversight weakens, the risk of material misstatement in public company financials rises. That risk does not manifest uniformly—it concentrates in precisely the types of situations that forensic-oriented investors are trained to identify: complex revenue recognition arrangements, aggressive capitalization of development costs, off-balance-sheet structures, and subjective fair value measurements where management has wide latitude.

The data bears this out. PCAOB inspection results have consistently shown elevated deficiency rates among mid-tier and smaller audit firms—precisely the firms that audit the small- and mid-cap companies where informational asymmetries are most pronounced and where activist engagement often creates the most value. In 2023, deficiency rates at mid-tier firms reached 63.8 percent, while triennially inspected non-affiliated firms posted rates of 67 percent.[2] [8] Preliminary 2024 data showed meaningful improvement—the aggregate deficiency rate across all firm categories dropped approximately seven percentage points year over year, with mid-tier firms declining to 50 percent and triennially inspected non-affiliated firms declining to 61 percent—but the rates remain elevated by historical standards.[2] [8]

A study published in Contemporary Accounting Research found that PCAOB-identified audit deficiencies are positively associated with future financial misstatements across the inspected firm’s entire client portfolio—and that the single most predictive type of deficiency is an auditor’s failure to understand the client’s accounting procedures or policies.[7] In other words, when the PCAOB identifies problems, those problems tend to be real and consequential for investors.

Weakening the institution that surfaces these problems does not eliminate the underlying risk. It simply makes the risk harder to see.

The Mid-Tier Audit Firm Blind Spot

One dimension of this issue that deserves more attention from institutional allocators is the concentration of audit quality risk at mid-tier and smaller firms. The Big Four—Deloitte, EY, KPMG, and PwC—audit the vast majority of large-cap public companies and, while not immune to deficiencies, have substantially more resources to invest in quality control systems, technology, and talent.

But as you move down the capitalization spectrum into the small- and micro-cap universe—where active managers, activist funds, and event-driven strategies tend to operate—the landscape shifts. Companies in this segment are more likely to be audited by firms with higher deficiency rates, fewer internal resources, and less regulatory visibility. The PCAOB’s triennial inspection cycle for smaller firms means that some audit firms are inspected only once every three years, leaving multi-year windows during which deteriorating audit quality may go undetected.[8]

For investors conducting due diligence on potential portfolio companies, the identity and inspection history of the company’s external auditor should be treated as a material consideration—not an administrative footnote. PCAOB inspection reports are publicly available, and the data is now downloadable in machine-readable formats.[2] Institutional investors who are not incorporating auditor quality metrics into their research processes are, in our view, leaving a meaningful risk variable unexamined.

The Investor’s Imperative

The debate over the PCAOB’s future will continue. Legislative attempts to fold it into the SEC may resurface outside the reconciliation process. Budget reductions may constrain inspection coverage. Internal policy shifts may soften enforcement posture. And the broader governance landscape—from evolving proxy voting frameworks[10] to new SEC guidance redefining the boundaries between passive and active ownership[5]—is adding layers of complexity to the institutional investor’s operating environment.

None of these outcomes are within the control of individual investors. What is within their control is the rigor of their own analytical processes. In an environment where the external quality assurance infrastructure may be under strain, the burden of verification shifts—at least in part—back to the investor. Forensic accounting analysis, independent verification of reported financial data, and disciplined scrutiny of audit committee composition and auditor selection are not luxuries reserved for specialized activists. They are increasingly table-stakes competencies for any institutional investor deploying capital on the basis of public company financial statements.

At Buxton Helmsley, this has always been the foundation of our approach. We believe that transparency, accuracy, and accountability in financial reporting are not regulatory abstractions—they are the preconditions for efficient capital allocation and the protection of investor interests. When external oversight contracts, the case for rigorous, independent analysis only strengthens.

The question is not whether the PCAOB will survive in its current form. The question is whether investors are prepared for the possibility that it may not—and whether their analytical frameworks are robust enough to compensate for whatever gaps may emerge.

Investors who are prepared will be positioned to identify risk before it becomes a headline. Those who are not may find themselves relying on an audit opinion that was never as reliable as they assumed.

Referenced Sources

[1] Congressional Budget Office, Cost Estimate for Provisions Affecting the Public Company Accounting Oversight Board (May 7, 2025).

[2] Public Company Accounting Oversight Board, Staff Spotlight: Significant Improvements Across Largest Firms, Alongside Inspection Results in Record Time (March 31, 2025).

[3] Public Company Accounting Oversight Board, Board Member Statement, Adoption of the 2026 Budget—Missed Opportunities for Good Fiscal Stewardship (2025).

[4] Public Company Accounting Oversight Board, Board Member Speech, Audit Regulations 2025 & Beyond—Restoring Trust in Public Company Audits and Capital Markets (2025).

[5] Gibson, Dunn & Crutcher LLP, The Passive/Aggressive Investor: Significant New SEC Staff Interpretive Guidance on Schedule 13G Eligibility (October 14, 2025).

[6] U.S. Securities and Exchange Commission, Division of Examinations, 2026 Examination Priorities (November 17, 2025).

[7] Constance et al., “PCAOB Inspection Deficiencies and Future Financial Reporting Quality: Do the Types of Deficiencies Matter?” Contemporary Accounting Research (2025).

[8] Palmer, R., “Insights from Fifteen Years of PCAOB Inspections,” The CPA Journal (January 2026).

[9] Garcia, R., DiGuiseppe, M., and Berlin, A. (PricewaterhouseCoopers), “2026 Corporate Governance Trends to Watch,” Harvard Law School Forum on Corporate Governance (February 8, 2026).

[10] Weil, Gotshal & Manges LLP, Looking to the 2026 Proxy Season: Key Corporate Governance, Engagement, Disclosure and Annual Meeting Topics (February 5, 2026).

This publication is one of the Insights commentaries of Buxton Helmsley USA, Inc. (“Buxton Helmsley”).  It reflects the opinions, analysis, and interpretations of Buxton Helmsley as of the date of publication, and it is based upon information that Buxton Helmsley believes to be accurate and that is derived from public sources or from other sources believed to be reliable.  Buxton Helmsley does not represent or warrant that such information is accurate or complete, and it should not be relied upon as such.  The views expressed are subject to change at any time, and Buxton Helmsley undertakes no obligation to update this publication or to correct any information contained within it.

Except for statements expressly attributed to an identified source or to a public filing, the statements in this publication constitute the opinions and good-faith analysis of Buxton Helmsley and are not statements of objective fact.  Buxton Helmsley’s analysis may rest upon assumptions, estimates, and interpretations that could prove to be incorrect.  Any reference to a potential violation, misstatement, impropriety, or deficiency reflects Buxton Helmsley’s analytical conclusions and opinions, and does not represent a finding by any court, regulator, or other authority.  Readers should conduct their own investigation and analysis of any company, security, or matter discussed.  Any company or person referenced that believes any statement in this publication to be inaccurate is invited to contact Buxton Helmsley at general@buxtonhelmsley.com, and Buxton Helmsley will give good-faith consideration to any correction supported by credible evidence.

This publication is provided for informational purposes only.  It does not constitute, and should not be construed as, investment advice, a recommendation, or the provision of any individualized investment advisory service to any person, nor an offer or solicitation to buy, sell, or hold any security.  Nothing in this publication takes into account the particular investment objectives, financial situation, or needs of any reader.  No reader should construe this publication as creating any advisory, fiduciary, or other relationship between Buxton Helmsley and such reader.  Readers should consult their own legal, tax, accounting, and financial advisers before making any investment decision.

As of the date of this publication, Buxton Helmsley, the funds and accounts that it manages or advises, and its principals hold no position in the securities of the companies mentioned in the article.  Buxton Helmsley and the foregoing persons may, at any time and without further notice, purchase, sell, cover, or otherwise change any position in any security discussed in this publication, including in a manner inconsistent with the opinions expressed herein, for various reasons, including but not limited to new research discoveries.  Buxton Helmsley may realize gains in the event that the price of any security discussed moves in a direction consistent with a position that it holds.

Buxton Helmsley has not received, and will not receive, any compensation from any third party—including any issuer discussed in this publication or any person holding an interest in any such issuer—in connection with the preparation or publication of this commentary, except as expressly disclosed in this publication.  Buxton Helmsley was not engaged or compensated by any third party to publish this commentary, except as expressly disclosed in this publication.

This publication is not, and shall not be construed as, an offer to sell or a solicitation of an offer to buy any security or any interest in any fund or other investment vehicle managed or advised by Buxton Helmsley or any of its affiliates, nor is it an advertisement for any such fund, vehicle, or advisory service.  Any such offer or solicitation will be made only by means of definitive offering documents, and only to eligible investors, in accordance with applicable law.

This publication is intended only for distribution to, and use by, persons in the United States.  It is not directed to, intended for, or to be relied upon by, any person located in any jurisdiction outside the United States, and it does not constitute an offer, solicitation, or provision of any service in any such jurisdiction.  Persons who access this publication from outside the United States do so on their own initiative and are responsible for compliance with the laws applicable to them.

This publication may contain forward-looking statements that reflect Buxton Helmsley’s current expectations and that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed.  Past performance is not indicative of, and does not guarantee, future results.  No representation is made that any investment will achieve, or is likely to achieve, results comparable to those discussed.

To the fullest extent permitted by applicable law, neither Buxton Helmsley nor any of its affiliates, nor their respective principals, members, officers, employees, or agents, shall have any liability to any person for any direct, indirect, incidental, consequential, or other loss or damage arising from any use of, or reliance upon, this publication or any information contained within it.

If any provision of these disclosures is held to be invalid or unenforceable, the remaining provisions shall continue in full force and effect.

© 2026 Buxton Helmsley USA, Inc.  All rights reserved.  This publication may not be reproduced or redistributed, in whole or in part, without attribution to Buxton Helmsley.